| Literature DB >> 34953059 |
Adriaan Penson1, Iris Walraven2, Ewald Bronkhorst3, Martha A Grootenhuis4, Wim J E Tissing5,6, Helena J H van der Pal5, Andrica C H de Vries7, Marry M van den Heuvel-Eibrink5,8, Sebastian Neggers5,9, Birgitta A B Versluys5, Marloes Louwerens10, Saskia M F Pluijm5, Nicole Blijlevens1, Margriet van der Heiden-van der Loo5, Leontien C M Kremer5,11, Eline van Dulmen-den Broeder12, Hans Knoop13, Jacqueline Loonen1.
Abstract
BACKGROUND: Fatigue is often reported by patients with childhood cancer both during and after cancer treatment. Several instruments to measure fatigue exist, although none are specifically validated for use in childhood cancer survivors (CCS). The aim of the current study was to present norm values and psychometric properties of the Checklist Individual Strength (CIS) and Short Fatigue Questionnaire (SFQ) in a nationwide cohort of CCS.Entities:
Keywords: checklist individual strength; childhood cancer survivors; psychometric properties; severe fatigue; short fatigue questionnaire
Mesh:
Year: 2021 PMID: 34953059 PMCID: PMC8855897 DOI: 10.1002/cam4.4490
Source DB: PubMed Journal: Cancer Med ISSN: 2045-7634 Impact factor: 4.452
Participant characteristics (n = 2073)
| Characteristic | No. | % |
|---|---|---|
| Sex | ||
| Male | 1055 | 50.9 |
| Female | 1018 | 49.1 |
| Age at participation (years) | ||
| <20 | 67 | 3.2 |
| 20–29 | 593 | 28.7 |
| 30–39 | 770 | 37.1 |
| ≥40 | 643 | 31.0 |
| Age at diagnosis (years) | ||
| 0–5 | 972 | 46.9 |
| 5–10 | 554 | 26.7 |
| 10–15 | 431 | 20.8 |
| 15–18 | 116 | 5.6 |
| Primary childhood cancer diagnosis | ||
| Leukemia | 736 | 35.5 |
| Non‐Hodgkin lymphoma | 243 | 11.7 |
| Hodgkin lymphoma | 141 | 6.8 |
| CNS | 192 | 9.3 |
| Neuroblastoma | 124 | 6.0 |
| Retinoblastoma | 11 | 0.5 |
| Renal tumors | 237 | 11.4 |
| Hepatic tumors | 18 | 0.9 |
| Bone tumors | 121 | 5.8 |
| Soft tissue tumors | 146 | 7.1 |
| Germ cell tumors | 72 | 3.5 |
| Other and unspecified | 32 | 1.5 |
| Period of childhood cancer diagnosis | ||
| 1960–1969 | 31 | 1.5 |
| 1970–1979 | 284 | 13.7 |
| 1980–1989 | 640 | 30.9 |
| >1990 | 1118 | 53.9 |
| Childhood cancer treatment | ||
| Surgery only | 143 | 6.9 |
| Chemotherapy, no radiotherapy | 1112 | 53.6 |
| Radiotherapy, no chemotherapy | 106 | 5.1 |
| Radiotherapy and chemotherapy | 700 | 33.8 |
| No treatment or treatment unknown | 12 | 0.6 |
Diagnostic groups included all malignancies covered by the third edition of the International Classification of Childhood Cancer (ICCC‐3).
Includes all morphology codes specified in the ICCC‐3 under lymphomas and reticuloendothelial neoplasms, except for Hodgkin lymphomas.
Includes all morphology codes specified in the ICC‐3 under other malignant epithelial neoplasms and malignant melanomas and other and unspecified malignant neoplasms.
Treatment data included primary treatment and all recurrences.
Norm values for the CIS and SFQ
|
| Mean (SD) | 25th | 50th | 75th | |
|---|---|---|---|---|---|
| CIS | |||||
| Fatigue severity (range 8–56) | 2059 | 25.89 (13.14) | 14.0 | 24.0 | 36.0 |
| Concentration (range 5–35) | 2055 | 14.98 (7.82) | 9.0 | 13.0 | 21.0 |
| Motivation (range 4–28) | 2061 | 10.36 (5.38) | 6.0 | 9.0 | 14.0 |
| Activity (range 3–21) | 2060 | 9.24 (5.23) | 5.0 | 8.0 | 13.0 |
| Total score (range 20–140) | 2038 | 60.44 (26.85) | 38.0 | 57.0 | 80.0 |
| SFQ | |||||
| Total score (range 4–28) | 1998 | 13.36 (7.32) | 7.0 | 13.0 | 19.0 |
Sum scores were calculated when all items for that particular scale were completed by the participant.
Pearson's correlations between total scores of the CIS and SFQ and subscales of the TAAQOL and SF‐36
| CIS | SFQ | |
|---|---|---|
| TAAQOL | ||
| Vitality | −0.857 | −0.889 |
| Sleep | −0.471 | −0.451 |
| Depressive emotions | −0.574 | −0.507 |
| SF−36 | ||
| Vitality | −0.841 | −0.844 |
| Emotional role functioning | −0.522 | −0.461 |
All correlations were statistically significant (p < 0.01).
Sensitivity, specificity, positive prediction value (PPV), and negative prediction value (NPV) of several SFQ cut‐off scores
| SFQ total score | Sensitivity % | Specificity % | PPV % | NPV % |
|---|---|---|---|---|
| 16 | 97.0 | 81.8 | 68.1 | 98.6 |
| 17 | 95.4 | 87.0 | 74.7 | 97.9 |
| 18 | 92.6 | 91.3 | 81.0 | 96.9 |
| 19 | 86.1 | 94.6 | 86.5 | 94.4 |
| 20 | 75.9 | 97.2 | 91.5 | 90.9 |